Meningococcal Group B Vaccine comment watch save
BreastfeedingGeriatricPediatric

  • TRADE NAMES: Bexsero (Novartis); Trumenba (Wyeth)
  • INDICATIONS: Immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B
  • CLASS: Vaccine
  • HALF-LIFE: N/A
  • FDA APPROVAL DATE: 10/29/2014
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    None known

Please login to view the rest of this drug profile.

Page last updated 07/31/2023

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top